
Project
Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy (MITI2)
Acronym
MITI2
Funding
Horizon 2020
Funding scheme
RIA – Research and Innovation action
Start Date
01/05/2023
End Date
30/04/2027
Consortium
INSERM – Institut National de la Santé et de la Recherche Médicale
Metatissue
BEOnChip
Fondation De Coopération Scientifique
Hochschule Kaiserslautern
CNRS – Centre National de la Recherche Scientifique
Inserm Transfert
Eligible Total Cost
6.383.217€
Resume
Inflammatory bowel disease (IBD) refers to a group of chronic conditions that cause inflammation in the digestive tract. IBD requires long-term management and treatment, which includes medication, lifestyle changes, and sometimes surgical intervention to control symptoms and reduce inflammation. Funded by the HORIZON programme, the MITI 2 project aims to investigate the regulatory properties of a specific subset of microbiota-specific regulatory T cells previously associated with positive clinical outcomes in IBD. The consortium will develop an ex vivo human preclinical model that mimics the complex microenvironment of the human gut and will study the effectiveness of an immunotherapy approach that harnesses these specialised regulatory T cells3
Know more
https://cordis.europa.eu/project/id/101080445
https://miti2.eu/

Interlynk has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101080445